Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Clopidogrel→

Clopidogrel Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
113665-84-2
Molecular formula
C16H16ClNO2S
Molecular weight
321.8 g/mol
Drug class
Thienopyridine antiplatelet prodrugirreversible P2Y12 ADP-receptor antagonist
Mechanism of action
Requires hepatic bioactivation to an active thiol metabolite that irreversibly binds platelet P2Y12 receptors, inhibiting ADP-mediated activation of the glycoprotein IIb/IIIa complex and platelet aggregation.
Indications / reported uses
  • Prevention of atherothrombotic events in patients with recent myocardial infarction, recent ischaemic stroke or established peripheral arterial disease
  • Acute coronary syndrome, including non-ST-elevation and ST-elevation myocardial infarction, in combination with aspirin under the applicable label
  • Prevention of stent thrombosis after percutaneous coronary intervention as part of dual antiplatelet therapy; duration is patient- and product-specific

Sources: US DailyMed — Clopidogrel tablets · NLM MeSH — Clopidogrel · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Clopidogrel Environmental Risk Assessment (ERA) (the Clopidogrel ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.